These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36811662)

  • 41. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
    Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
    JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.
    Huang C; Zhu XD; Ji Y; Ding GY; Shi GM; Shen YH; Zhou J; Fan J; Sun HC
    BMC Cancer; 2017 Jan; 17(1):58. PubMed ID: 28095820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis.
    Chen ZH; Zhang XP; Wang H; Chai ZT; Sun JX; Guo WX; Shi J; Cheng SQ
    HPB (Oxford); 2019 Aug; 21(8):935-944. PubMed ID: 30871805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study.
    Yuan L; Feng J; Zhang Y; Lu C; Xu L; Liang C; Liu Z; Mao F; Xiang Y; Wang W; Wang K; Cheng S
    Eur J Surg Oncol; 2023 Jul; 49(7):1226-1233. PubMed ID: 36739252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review.
    Zhang R; Wang F; You Z; Deng D; He J; Yan W; Quan J; Wang J; Yan S
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):82. PubMed ID: 38319412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
    Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
    PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.
    Shen A; Liu M; Zheng D; Chen Q; Wu Z
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):142-154. PubMed ID: 31303533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
    Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
    J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis.
    Liu SJ; Yan LJ; Wang HC; Ding ZN; Liu H; Zhang X; Pan GQ; Han CL; Tian BW; Yang XR; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
    Oncologist; 2024 Jun; ():. PubMed ID: 38940446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.
    Huang G; Xiong H; Li S; Zhu Y; Liu H
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):5. PubMed ID: 38170235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis.
    Xian F; Wu C; Zhang G; Xu G
    Medicine (Baltimore); 2022 Nov; 101(44):e31479. PubMed ID: 36343054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients.
    Balcar L; Bauer D; Pomej K; Meischl T; Mandorfer M; Reiberger T; Trauner M; Scheiner B; Pinter M
    PLoS One; 2023; 18(4):e0282680. PubMed ID: 37027398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.
    Ma D; Liu M; Zhai X; Li X; Jin B; Liu Y
    Front Immunol; 2023; 14():1215745. PubMed ID: 37520554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
    Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.
    Li T; Guo J; Liu Y; Du Z; Guo Z; Fan Y; Cheng L; Zhang Y; Gao X; Zhao Y; He X; Wu W; Gao N; Wu Y; Li J; Zhang Y; Kang W; Cai Z; Wang W; Li X; Zan Y; Nguyen MH; Ji F
    Cancer Immunol Immunother; 2023 Jul; 72(7):2137-2149. PubMed ID: 36840762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
    Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ning C; Zhang X; Wang Y; Yang X; Yang X; Chao J; Xun Z; Xue J; Wang Y; Sun H; Li Y; Zhang N; Zhu C; Hou X; Sang X; Zhao H
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1461-1471. PubMed ID: 37433375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.